

CLINICAL REVIEW

Practical Applications of Fish Oil (Ω -3 Fatty Acids) in Primary Care

Robert Oh, MD

Background: Fish oil (Ω -3 fatty acids) has been studied for more than 30 years. However, recent concerns of mercury and environmental toxins have clouded fish oil's potential clinical benefits. This article aims to review practical, evidence-based applications of fish oil for the primary care physician.

Methods: PubMed search using key words 'fish oil,' 'docosahexaenoic,' and 'eicosapentaenoic' in title/abstract. Limited to human clinical trials. Articles were further scanned for relevant sources.

Results: For secondary prevention of cardiovascular disease, 1 g of fish oil has shown to reduce overall and cardiovascular mortality, myocardial infarction, and sudden cardiac death. Higher doses may be used for its potent triglyceride-lowering effects and for patients with rheumatoid arthritis to reduce nonsteroidal anti-inflammatory use. Ω -3 fatty acid supplementation of infant formula has shown benefit in infant neural growth and development. With the potential health benefits of fish, women of childbearing age should be encouraged to eat 1 to 2 low-mercury fish meals per week.

Conclusions: Fish oil has numerous practical applications for the primary care physician. Understanding the diverse clinical research of Ω -3 fatty acids and fish oil is important in determining its role in primary care practices. (J Am Board Fam Pract 2005;18:28–36.)

More than 30 years ago, Danish researchers hypothesized that lower rates of heart disease of Greenland Eskimos were associated with higher consumption of whale, seal, and fish.^{1,2} Since then, from research unraveling the mechanism of Ω -3 fatty acids, to clinical trials in cardiovascular disease, treatments of hyperlipidemia, rheumatoid arthritis, and the prevention of preterm labor, there have been more than 7000 reports—including nearly 900 human clinical trials on the study of fish oil and Ω -3 fatty acids.^{3,4} However, recent concerns regarding mercury and other environmental toxins have clouded the waters of fish oil research and its potential health benefits. This article will discuss the evidence behind fish oil—emphasizing current, practical information for conditions family physicians can effectively impact today.

Methods

Medline and Cochrane database search using the key words "fish oil" or "docosahexaenoic" or "eicosapentaenoic." These were combined with the keywords "cardiovascular disease," "myocardial infarction," "hypertriglyceridemia," "pregnancy," "rheumatoid arthritis," or "infants." Search was further limited to humans, clinical trials. References from key articles were also scanned for relevant sources.

Results and Discussion

Mechanism of Action

There are 2 classes of essential fatty acids, the Ω -6 and Ω -3 fatty acids (FA). Ω -3 FA, found primarily in fatty fish with high oil content, consists of both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Research has shown increasing evidence for anti-inflammatory, antithrombotic, anti-arrhythmic and antiatherogenic effects of fish oil.⁵ Fish oil is the most significant source of dietary Ω -3 FA. The terms will be used interchangeably.

Arachidonic acid, an Ω -6 FA, is converted into inflammatory prostaglandins and leukotrienes via the enzymes cyclooxygenase and lipoxygenase, respectively (Figure 1). Increased intake of Ω -3 FA reduces incorporation of arachidonic acid into cell

Submitted, revised, 26 July 2004.

From the Department of Family Medicine, MCHJ-FP, Madigan Army Medical Center, Ft. Lewis, Washington. Address correspondence to: Robert Oh, MCHJ-FP, Madigan Army Medical Center, Ft. Lewis, WA 98431 (e-mail: roboh98@earthlink.net).

The opinions or assertions contained herein are the private views of the author and are not to be construed as official or as reflecting the views of the Department of Defense.




Figure 1. Arachidonic acid is converted to leukotrienes by the enzyme lipoxygenase (LPO) and to thromboxane A2 and prostaglandins by the enzyme cyclooxygenase (COX). Ω -3 fatty acids, in essence, reduce the breakdown of arachidonic acids.

membranes, thereby promoting a net anti-inflammatory response. Indeed, fish oil has been shown to significantly decrease potent inflammatory markers, including leukotrienes, prostaglandins, interleukins, and tumor necrosis factor.^{6,7} The inhibition of arachidonic acid by Ω -3 FA also produces a potential antithrombotic effect by decreasing production of thromboxane A2. Membrane stabilization in cardiac tissue by Ω -3 FA confers potential antiarrhythmic effects,⁸ whereas triglyceride-lowering effects are caused by the reduction and secretion of very low density lipoprotein particles from the liver.⁵ With its unique and varied mechanism of actions, the potential uses of fish oil have been studied in various clinical situations.

Clinical Uses

Cardiovascular Disease

The benefits of fish oil in cardiovascular disease provide the strongest and most compelling evidence favoring its use in practice. Numerous observational studies have shown that Ω -3 FA enriched diets are associated with reduction of cardiovascular mortality, myocardial infarction, and sudden death. Higher fish intake was associated with decreased incidence of coronary artery disease and cardiovascular mortality in several prospective cohort studies.⁹⁻¹¹ Another large prospective cohort study reported a marked reduction in sudden cardiac death associated with dietary fish intake.^{12,13} Putting it in perspective, a minimum of one fish meal a week was associated with a 52% reduction in sudden cardiac death. Some observational trials do not show a beneficial relationship for fish intake. This may be related to differences in

background cardiovascular risk, fish intake, or lifestyle behaviors of study populations and study definitions of sudden death and fish intake.¹⁴ Although the intake of fish oil in these studies was not sufficient to produce a marked anti-inflammatory or triglyceride-lowering effect, both antiarrhythmic properties and membrane stabilization of cardiac tissue by fish oils has been proposed as its mechanism of action.⁸

Randomized clinical trials add to the growing evidence—especially for secondary prevention of cardiovascular disease. A randomized placebo-controlled trial showed that supplementing patients with recent history of a myocardial infarction (MI) with 1.8 g of fish oil for 1 year decreased total cardiac events by 29% [number needed to treat (NNT) = 10 for 1 year; $P < .05$]. Both total cardiac deaths and nonfatal MI were also reduced by 48% (NNT = 8.1 for 1 year; $P < .01$ and NNT = 9.8 for 1 year; $P < .01$; respectively)¹⁵ [level of evidence-1 (LOE)]. The Diet and Reinfarction Trial (DART),¹⁶ randomized 2033 men with myocardial infarction into different dietary groups. Men randomized to fatty fish diet had a 29% reduction in the 2-year all-cause mortality compared with those who did not receive this advice (NNT = 28 for 2 years; $P < .05$). Most of the benefits resulted from the reduction of cardiovascular deaths (NNT = 27 for 2 years; $P < .01$) (LOE-1). The GISSI¹⁷ trial randomized 11,324 Italian men who had suffered a myocardial infarction within 3 months. Compared with the control group, patients supplemented with fish oil 850 mg showed a 15% reduction in the primary endpoints (death, nonfatal myocardial infarction and stroke) after 3.5 years (NNT = 48 for

Table 1. American Heart Association (AHA) Recommendations for Fish Oil*

Patient Population	Recommendations
Patients WITHOUT documented coronary heart disease	Eat a variety of (preferably fatty) fish at least twice a week. Include oils and foods rich in α -linolenic acid (flaxseed, canola, and soybean oils; flaxseed and walnuts)
Patients WITH documented coronary heart disease	Consume approximately 1 g of EPA+DHA per day, preferably from fatty fish. EPA+DHA supplements could be considered in consultation with the physician.
Patients who need to lower triglycerides	2–4 g of EPA+DHA per day provided as capsules under a physician's care.

* <http://www.americanheart.org/presenter.jhtml?identifier=4632>

3.5 years; $P = .008$) (LOE-1). It is striking that most of the benefit was derived from a 30% reduction in cardiac mortality and a 45% reduction in sudden death. Mortality reduction was significant in just 3 months of fish oil therapy—even in light of optimal pharmacologic therapy with antiplatelet agents, angiotensin inhibitors, and lipid lowering therapy.¹⁸

Finally, a meta-analysis¹⁹ and a recent systematic review²⁰ launched by the Agency for Health Care Research and Quality (AHRQ), found favorable effects of fish oil on cardiovascular and overall mortality. With this mounting evidence, the American Heart Association,¹⁴ recommends 1 g of fish oils in all patients with documented coronary artery disease via diet or through supplementation after consultation with their physician [strength of recommendation (SOR)-A] (Table 1).

Hypertriglyceridemia

High triglycerides have been recognized as an independent risk factor for coronary artery disease. The Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III),²¹ recommends treating hypertriglyceridemia more aggressively. However, medications to treat hypertriglyceridemia (such as fibric acid derivatives and niacin) are limited and can have serious side effects. Even with medications, hypertriglyceridemia can be difficult to treat without using a combination of drugs.

A review of over 70 clinical trials²² and a recent systematic review by the AHRQ²³ have demonstrated the consistent and potent triglyceride lowering effects of fish oil supplementation. In an early trial, mean triglycerides were reduced 79% (from 1432 to 282 mg/dL) using 20 g of fish oil. ($P <$

.01).²⁴ More recently, in patients with severe hypertriglyceridemia (mean = 919 mg/dL), 3.4 g of fish oil showed a triglyceride reduction 45% compared with controls ($P < .0001$).²⁵

Although studies are limited, combination therapy with a statin seems to be safe and the results additive. Adding 3 g of fish oil to 40 mg of pravastatin reduced triglycerides an additional 33%.²⁶ Another study, combining 3.4 g of fish oil daily in patients with persistent hypertriglyceridemia on 10 to 40 mg simvastatin, showed additional reduction in triglycerides by 20% to 30%, without serious adverse effects.²⁷ Another trial, however, using 10 mg of atorvastatin and 1.7 g of fish oil, did not show significant difference from baseline. This trial may have been limited by their lower dosage of fish oil and the higher background fish consumption by the patients.²⁸

Overall, there is a dose-dependent lowering of triglycerides with higher fish oil supplementation. Although on average, low density lipoprotein (LDL) cholesterol rose 10 mg/dL and high-density lipoprotein 3 mg/dL, these were nonsignificant.²³ There were no significant changes in total cholesterol. Use of 2 to 4 g of fish oil, which lowers triglycerides by 20% to 50%, may be recommended for patients with mild or persistent hypertriglyceridemia to reach ATP III goals (SOR-A) (Table 1).^{14,21}

Rheumatoid Arthritis

In patients with rheumatoid arthritis (RA), over 15 clinical trials and 2 meta-analyses favor the use of fish oil.^{29,30} Fish oil supplementation consistently shows modest clinical improvement and reduction of nonsteroidal anti-inflammatory drug (NSAID) use in randomized clinical trials. One trial compared approximately 2.8 g of fish oil versus placebo

Table 2. Clinical Uses and Recommendations

Clinical Use	Dosage	Comments	Strength of Recommendation
Secondary prevention of cardiovascular disease	1–2 g/day	May encourage dietary intake, or fish oil supplementation	A ^{19,20}
Hypertriglyceridemia	Initial 2–4 g; up to 12 g	For doses greater than 3 g, consider monitoring for bleeding side effects, LDL, and glycemic response	A ²³
Rheumatoid arthritis	2.6–6 g may initiate at 90 mg/kg; maintenance dose 45 mg/kg	May take 8–12 weeks for clinical response; consider tapering NSAIDs; compliance may be an issue	A ^{29,30}
Infants (not breast-feeding)	0.35% of dietary fat as DHA	Consider Ω -3 and Ω -6 enriched infant formula	B ^{42,43}
Women (pregnant and of childbearing age)	2 fatty fish meals a week (up to 12 oz)	Avoid shark, tile fish, king mackerel, swordfish. Limit albacore tuna to 6 oz per week.	C ^{47,48,66}

in 64 patients with stable RA. In 3 months, the fish oil group showed significant reduction of NSAID use compared with placebo. This effect peaked at 12 months and was not associated with any clinical deterioration (LOE-2).³¹ A double-blind placebo-controlled trial showed that fish oil supplementation of 130 mg/kg/day decreased the number of tender joints, duration of morning stiffness, pain, and global arthritis activity versus placebo (LOE-2).³²

Reduction of tumor necrosis factor, interleukin levels, and other anti-inflammatory mediators has been hypothesized as the main effect of Ω -3 FA in RA. However, others recognize the importance and synergistic effects of a higher intake of Ω -3 FA in conjunction with lower dietary intake of Ω -6 FA. A double-blind placebo controlled trial using lower doses of fish oil (40 mg/kg; average, 2.3 g) in a background of low dietary Ω -6 showed clinical improvement compared with placebo over 15 weeks ($P < .02$) (LOE-2).³³ Clinical improvements were similar to studies using higher doses. Another recent randomized controlled trial showed clinical benefits, reduction of NSAID, and corticosteroid use with low-dose fish oil supplementation (30 mg/kg; average, 2 g) in patients with diets low in Ω -6 FA.³⁴ Effects were significant at 3 months and peaked at 6 to 8 months (LOE-1).

For the family physician, although fish oil supplementation may benefit clinical symptoms of RA, its potential to reduce or even eliminate NSAID use³⁵ may be the most useful in clinical practice. NSAIDs, although highly effective for pain control, has serious side effects that often limits its use. Overall, doses of 2.6 to 6 g (or weight-based) of fish

oil given for a minimum of 8 to 12 weeks is optimal (SOR-A) (Table 2).^{32,36}

Mothers and Infants

Ω -3 FA use in pregnancy has shown promise in prolonging gestation and the prevention of preterm labor.³⁷ A randomized double-blind controlled trial showed that supplementation with eggs enriched with 133 mg of DHA prolonged gestation by 6 days compared with women given regular eggs ($P < .01$).³⁸ Looking at women at high risk for preterm delivery, a multicenter study supported the use of fish oil in prolonging gestation.³⁹ Women supplemented with 2.7 g of fish oil showed significantly reduced preterm delivery rates, increased mean birth weight by 209 g, and increased duration of pregnancy by 8.5 days compared with the control group (LOE-1). Fish oil's inhibition of arachidonic acid and its subsequent reduction of prostaglandins have been thought to be a potential mechanism of action.

In 2002, the Food and Drug Administration (FDA) approved supplementation of both Ω -3 and Ω -6 FA in infant formula. Both are potentially important in fetal and infant neural development, in that DHA and arachidonic acid have been shown to be incorporated into brain and retinal cell membranes—particularly during the third trimester and early infant life. In both preterm and term infants, evidence consistently shows benefit of visual improvement at 4 months compared with infants fed nonsupplemented formula.^{40,41} Systematic analysis and meta-analysis have shown that higher DHA content of formula is significantly related to improved visual acuity (LOE-1).^{42,43} However, bene-

fit beyond 4 months is controversial. One recently completed trial showed visual improvement at 12 months in term infants given formula supplemented with Ω -3 FA compared with nonsupplemented formula.⁴⁴ Another study showed sustained increase in intelligence at 4 years of age in children whose mothers were supplemented with fish oil from 18 weeks of pregnancy to 3 months postpartum (LOE-2).⁴⁵

It is important to emphasize that breast-fed infants have outperformed infants fed Ω -3/ Ω -6 FA enriched formula in visual acuity measures. Although increasing dietary intake of fatty fish during the antepartum or breast-feeding period is a potentially attractive alternative to fish oil supplementation, it is unclear how much dietary Ω -3 FA intake is essential to maintain the benefit of DHA in breast milk.⁴⁶ Concerns of mercury content in fish also cloud its potential health benefits.⁴⁷

With fish oils' potential benefits in reduction of preterm labor, and improved neural and retinal growth for infants, it is prudent to recommend up to 2 low-mercury fish meals a week for women of childbearing age (SOR-C).⁴⁸ For infants, whereas breast milk continues to be superior over any formula, Ω -3 FA enriched formula should be considered in mothers who are not breast-feeding or have contraindications to breast-feeding.⁴⁹ It may be especially beneficial for preterm infants (SOR-B).

Other Conditions

With its potential anti-inflammatory actions and membrane stabilization properties, fish oil supplementation has been studied in a wide spectrum of conditions. Studies in inflammatory bowel disease,^{30,50-52} asthma,^{53,54} atopic dermatitis,⁵⁵ psoriasis,^{56,57} renal disease,^{30,58,59} and psychiatric illnesses^{60,61} are either inconsistent or the studies are limited. Studies in neurologic disorders such as ischemic stroke^{62,63} and Alzheimer disease⁶⁴ are beginning to be explored.

Safety Profile

Environmental Concerns

Concerns about mercury contamination and other environmental pollutants of fish have recently emerged.^{47,65} The FDA and the Environmental Protection Agency (EPA) jointly released an updated consumer advisory on fish intake in March 2004.⁴⁷ Pregnant women (including women planning to conceive), nursing mothers, and children

should avoid eating fish high in mercury—shark, king mackerel, swordfish, and tile fish. More significantly, this consumer advisory highlighted the importance of dietary fish. Women should eat 2 meals per week (up to 12 oz) of low-risk fish for its potential benefits in heart health and childhood growth and development. Fish should not be eliminated from the diet. Similar recommendations were recently issued from the United Kingdom's Food Standards Agency.⁶⁶

For men and those with known cardiovascular disease, physicians must be aware of the risks and benefits of Ω -3 FA to appropriately discuss any recommendations of fish intake or supplementation with their patients. Overall benefits of Ω -3 FA in secondary prevention of cardiovascular disease far outweigh any small potential risk for cancer and should not prevent the recommendation of fish oil supplementation for patients at-risk. EPA recommendations are based on the amount of fish intake necessary to raise risk of cancer by 1 case per 100,000.⁶⁷ The reduction of all-cause mortality of fish oil (NNT = 28 to 48) in secondary prevention of cardiovascular disease is similar to the landmark 4S (NNT = 30 for 5.4 years),⁶⁸ and CARE (NNT = 30 for 5 years)⁶⁹ trials of statin drugs. Although concerns regarding mercury in fish attenuating its cardiovascular benefits are debatable,^{70,71} it would be reasonable for patients to avoid those fish high in mercury.

Side Effects

Beyond the common and benign "fishy taste," increases in LDL levels, bleeding times, and a worsening glycemic profile in diabetics have all been raised as safety concerns of Ω -3 FA. Despite these concerns, Ω -3 FA is remarkably safe.⁷² LDL levels rose on average 10 mg/dL, but overall range was inconsistent and has no appreciable effects and may be caused by abnormally suppressed LDL levels.²³⁻²⁵ Although early studies raised concerns of a potential for clinical bleeding with high fish oil doses, use of 16 g of fish oil was clinically insignificant.⁷³ Finally, systematic reviews noted no significant difference in fasting glucose levels or glycemic control in patients with diabetes who received fish-oil supplements.^{30,74} In patients taking doses higher than 3 g/day, clinicians may consider monitoring for clinical bleeding and both LDL and glycemic response.

Table 3. Ω -3 Content in Fish (Cooked, Dry Heat)*

Fish	EPA & DHA† (mg per 100 g of edible fish; ~3–4 oz.)
Herring‡	1700
Salmon§	1600
Mackerel	1400
Flounder	500
Halibut¶	500
Tuna**	300
Bluefin	1500
Canned white	900
Canned light	300
Cod	200
Catfish	200
Haddock	200

* Approximated to nearest 100 mg (<http://www.nal.usda.gov/fnic/foodcomp/index.html>).

† EPA and DHA; EPA=20:5 Ω -3; DHA=22:6 Ω -3.

‡ Average; Atlantic and Pacific.

§ Average; Atlantic (wild and farmed), Chinook, pink, coho.

|| Average; Atlantic, Jack; Pacific, Spanish.

¶ Greenland halibut, 1100 mg.

** Skipjack/yellowfin, 300 mg.

Dosing, Diet and Formulation

A recent international working group convened by the National Institutes of Health recognized the dietary importance and potential essentiality of Ω -3 FA.⁴⁹ Adequate intake of 650 mg/day of foods rich in Ω -3 FA was recommended. The American Heart Association (AHA) issued similar guidance, advocating 1 g of Ω -3 enriched foods daily. However,

consistent supplementation may be difficult to maintain through dietary intake because of differences and awareness of Ω -3 FA content in different species of fish and food preparation techniques (Table 3).

Fish oil supplements provide the most consistent way of supplying higher doses of Ω -3 FA. Supplementation can be considered as an alternative to dietary intake for persons who are averse to a fish-enriched diet and may also be lower in mercury content and other environmental pollutants.⁷⁵ Most preparations provide approximately 300 mg of total Ω -3 FA, divided between EPA and DHA. Dose requirements greater than 3 g could potentially require more than 10 capsules per day. However, some highly concentrated versions provide up to 850 mg. Because the FDA does not regulate supplements, consumers are cautioned to buy from reputable and reliable brands. United States Pharmacopeia (USP) is an independent, nonprofit organization that verifies manufacturing, quality, and purity claims of supplements for supplement manufacturers who wish to participate. Those supplements branded as USP verified may improve its reliability and safety. Other companies guarantee purity content of their supplements (Table 4).

Conclusion

Fish saves lives, and physicians must recognize this potential life-saving treatment choice in patients with cardiovascular disease. In addition, family

Table 4. Components of Selected Fish Oil Products

Brand	Amount of EPA & DHA (mg per capsule)	Cost* (\$)	Number of capsules/day	Web Site
GNC Fish body oil	180/120	6.00	3–4	http://www.drugstore.com
Natrol Omega-3 complex	180/120	6.00	3–4	http://www.drugstore.com
Twinlab Omega-3	234/125	15.00	3	http://www.drugstore.com
Mega Twin EPA†	600/240	15.00	1–2	http://www.drugstore.com
OmegaRx†	400/200	25.00	2	http://www.zonenonline.com/fishoil_detail.asp?realname=
Ultimate Omega†	350/250	26.95	2	https://www.nordicnaturals.com/direct/prodsummary.asp?ID=30
TriOmega†	500 (total)	20.00	2	http://www.triomega.com
Kirkland Fish Oil‡	180/120	5.00	3–4	http://www.costco.com
Nature Made Fish Oil‡	216/144	7.00	3–4	http://www.drugstore.com

* 1-month supply, supplying 1 g of EPA/DHA.

† Pharmaceutical grade or makes claim regarding manufacturing process.

‡ United States Pharmacopeia-branded.

physicians can safely offer patients an alternative therapeutic approach for difficult-to-treat conditions such as hypertriglyceridemia and rheumatoid arthritis. For those without cardiovascular disease, including young mothers and women, it is reasonable to recommend 650 to 1000 mg of low-risk fish oils per day through dietary approaches as suggested by the National Institutes of Health working group, AHA, and the FDA—easily achieved by 1 to 2 fatty fish meals per week.

Understanding the diverse clinical research behind Ω -3 FA can aid family physicians—adding yet another weapon in their therapeutic arsenal for many diverse clinical conditions. This fish story however, is far from complete. Areas of future research include primary prevention trials, optimal intake of the ratio of Ω -6, Ω -3, DHA, and EPA, and continued research for various clinical indications. The availability of safe and reliable fish and supplements are paramount in further exploring and unlocking the health benefits of fish.

I thank the faculty development fellowship at Madigan Army Medical Center for their thoughtful and critical review of the manuscript.

References

1. Bang HO, Dyerberg J, Nielsew AB. Plasma lipids and lipoprotein pattern in Greenlandic west-coast Eskimos. *Lancet* 1971;1:1143–6.
2. Bang HO, Dyerberg J, Sinclair HM. The composition of the Eskimo food in north western Greenland. *Am J Clin Nutr* 1980;33:2657–61.
3. PubMed [database on the Internet]. Bethesda (MD): National Library of Medicine (US); 2002 [cited 2004 May 11]. Fish oil OR omega-3 OR docosahexaenoic OR eicosapentaenoic, limited to title/abstract [about 499 p.]. Available from: <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi>.
4. PubMed [database on the Internet]. Bethesda (MD): National Library of Medicine (US); 2002 [cited 2004 May 11]. Fish oil OR omega-3 OR docosahexaenoic OR eicosapentaenoic, limited to title/abstract, human, clinical trials [about 52 p.]. Available from: <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi>.
5. Holub BJ. Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care. *CMAJ* 2002;166:608–15.
6. Endres S, Ghorbani R, Kelly VE, et al. The effect of dietary supplementation with n-3 fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. *N Engl J Med* 1989;320:265–70.
7. Trebble TM, Wootton SA, Miles EA, et al. Prostaglandin E2 production and T cell function after

- fish-oil supplementation: response to antioxidant co-supplementation. *Am J Clin Nutr* 2003;78:376–82.
8. Leaf A, Kang JX, Xiao YF, Billman GE. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. *Circulation* 2003;107:2646–52.
9. Kromhout D, Bosschieter EB, de Lezenne CC. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. *N Engl J Med* 1985;312:1205–9.
10. Daviglius ML, Stamler J, Orenca AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. *N Engl J Med* 1997;336:1046–53.
11. Hu FB, Bronner L, Willett WC, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. *JAMA* 2002;287:1815–21.
12. Albert CM, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. *JAMA* 1998;279:23–8.
13. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. *N Engl J Med* 2002;346:1113–8.
14. Kris-Etherton PM, Harris WS, Appel LJ. AHA scientific statement: fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. *Circulation* 2002;106:2747–57.
15. Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival—4. *Cardiovasc Drugs Ther* 1997;11:485–91.
16. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). *Lancet* 1989;2:757–61.
17. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. *Lancet* 1999;354:447–55.
18. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. *Circulation* 2002;105:1897–903.
19. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. *Am J Med* 2002;112:298–304.
20. Wang C, Chung M, Lichtenstein A, et al. Effects of omega-3 fatty acids on cardiovascular disease. Evidence report/technology assessment number 94. AHRQ publication number 04-E009-1. Rockville (MD): Agency for Healthcare Research and Quality; 2004.

21. National Cholesterol Education Program. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. National Institutes of Health publication no. 02-5215. Bethesda (MD): National Heart, Lung, and Blood Institute; 2002. Available from: <http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm>
22. Harris WS. N-3 fatty acids and human lipoprotein metabolism: an update. *Lipids* 1999;34S:S257-8.
23. Balk E, Chung M, Lichtenstein A, et al. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evidence report/technology assessment no. 93. AHRQ publication no. 04-E010-2. Rockville (MD): Agency for Healthcare Research and Quality; 2004.
24. Phillipson BE, Rothrock DW, Connor WE, Harris WS, Illingworth DR. Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. *N Engl J Med* 1985;312:1210-6.
25. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. *J Cardiovasc Risk* 1997;4:385-91.
26. Contacos C, Barter PJ, Sullivan DR. Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. *Arterioscler Thromb* 1993;12:1755-62.
27. Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridemia. *Heart* 2001;85:544-8.
28. Nordoy A, Hansen JB, Brox J, Svensson B. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. *Nutr Metab Cardiovasc Dis* 2001;11:7-16.
29. Fortin PR, Lew RA, Liang MH, et al. Validation of a meta-analysis: the effects of fish oil in rheumatoid arthritis. *J Clin Epidemiol* 1995;48:1379-90.
30. MacLean CH, Mojica WA, Morton SC, et al. Effects of omega-3 fatty acids on lipids and glycemic control in type ii diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis. Evidence report/technology assessment no. 89. AHRQ publication no. 04-E012-1. Rockville (MD): Agency for Healthcare Research and Quality; 2004.
31. Lau CS, Morley KD, Belch JJ. Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis—a double blind placebo controlled study. *Br J Rheumatol* 1993;32:982-9.
32. Kremer JM, Lawrence DA, Petrillo GF, et al. Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal anti-inflammatory drugs. *Arthritis Rheum* 1995;38:1107-14.
33. Volker D, Fitzgerald P, Major G, Garg M. Efficacy of fish oil concentrate in the treatment of rheumatoid arthritis. *J Rheumatol* 2000;27:2343-6.
34. Adam O, Beringer C, Kless T, et al. Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis. *Rheumatol Int* 2003;23:27-36.
35. Kremer JM. N-3 fatty acid supplements in rheumatoid arthritis. *Am J Clin Nutr* 2000;71:349S-51S.
36. James MJ, Cleland LG. Dietary n-3 fatty acids and therapy for rheumatoid arthritis. *Semin Arthritis Rheum* 1997;27:85-97.
37. Olsen SF, Secher NJ. Low consumption of seafood in early pregnancy as a risk factor for preterm delivery: prospective cohort study. *BMJ* 2002;324:1-5.
38. Smuts CM, Huang M, Mundy D, Plasse T, Major S, Carlson SE. A randomized trial of docosahexaenoic acid supplementation during the third trimester of pregnancy. *Obstet Gynecol* 2003;101:469-79.
39. Olsen SF, Secher NJ, Tabor A, Weber T, Walker JJ, Gluud C. Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team. *BJOG* 2000;107:382-95.
40. SanGiovanni JP, Parra-Cabrera S, Colditz GA, Berkey CS, Dwyer JT. Meta-analysis of dietary essential fatty acids and long-chain polyunsaturated fatty acids as they relate to visual resolution acuity in healthy preterm infants. *Pediatrics* 2000;105:1292-8.
41. Koo WW. Efficacy and safety of docosahexaenoic acid and arachidonic acid addition to infant formulas: can one buy better vision and intelligence? *J Am Coll Nutr* 2003;22:101-7.
42. Uauy R, Hoffman DR, Mena P, Llanos A, Birch EE. Term infant studies of DHA and ARA supplementation on neurodevelopment: results of randomized controlled trials. *J Pediatr* 2003;143:S17-S25.
43. SanGiovanni JP, Berkey CS, Dwyer JT, Colditz GA. Dietary essential fatty acids, long-chain polyunsaturated fatty acids, and visual resolution acuity in healthy fullterm infants: a systematic review. *Early Hum Dev* 2000;57:165-88.
44. Hoffman DR, Birch EE, Castañeda YS, et al. Visual function in breast-fed term infants weaned to formula with or without long-chain polyunsaturates at 4 to 6 months: a randomized clinical trial. *J Pediatr* 2003;142:669-77.
45. Helland IB, Smith L, Saarem K, Saugstad OD, Drevon CA. Maternal supplementation with very long chain n-3 fatty acids during pregnancy and lactation augments children's IQ at 4 years of age. *Pediatrics* 2003;111:E39-E44.
46. Innis SM, Gilley J, Werker J. Are human milk long-chain polyunsaturated acids related to visual and neural development in breast-fed term infants? *J Pediatr* 2001;139:532-8.
47. FDA announces the revised consumer advisory on

- methylmercury in fish. Rockville (MD): Food and Drug Administration; 2004 [cited 2004 May 13]. Available from: <http://www.fda.gov/bbs/topics/news/2004/NEW01038.html>
48. Crawford LM. Fish is an important part of a balanced diet [monograph on the Internet]. Rockville (MD): Food and Drug Administration; 2004 [cited 2004 May 13]. Available from: <http://www.fda.gov/oc/opacom/hottopics/mercury/mercuryop-ed.html>.
 49. Simopoulos AP, Leaf A, Salem N Jr. Workshop statement on the essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. *Prostaglandins Leukot Essent Fatty Acids* 2000;63:119–21.
 50. Aslan A, Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double blind, placebo-controlled, crossover study. *Am J Gastroenterol* 1992;87:432–7.
 51. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. *N Engl J Med* 1996;334:1557–60.
 52. Belluzzi A, Boschi S, Brignola C, Munarini A, Cariani G, Miglio F. Polyunsaturated fatty acids and inflammatory bowel disease. *Am J Clin Nutr* 2000;71S:339S–42S.
 53. Woods RK, Thien FC, Abramson MJ. Dietary marine fatty acids (fish oil) for asthma in adults and children. *Cochrane Database Syst Rev* 2002;(3):CD001283.
 54. Schachter H, Reisman J, Tran K, et al. Health effects of omega-3 fatty acids on asthma. Evidence report/technology assessment no. 91. AHRQ publication no. 04-E013-2. Rockville (MD): Agency for Healthcare Research and Quality; 2004.
 55. Van Gool CJ, Zeegers MP, Thijs C. Oral essential fatty acid supplementation in atopic dermatitis—a meta-analysis of placebo-controlled trials. *Br J Dermatol* 2004;150:728–40.
 56. Soyland E, Funk J, Rajka G, Sandberg M, Thune P, Rustad L, et al. Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis. *N Engl J Med* 1993;328:1812–6.
 57. Mayser P, Mrowietz U, Arenberger P, et al. Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial. *J Am Acad Dermatol* 1998;38:539–47.
 58. Donadio JV Jr, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. *J Am Soc Nephrol* 1999;10:1772–7.
 59. Strippoli GF, Manno C, Schena FP. An “evidence-based” survey of therapeutic options for IgA nephropathy: assessment and criticism. *Am J Kidney Dis* 2003;41:1129–39.
 60. Stoll AL, Severus WE, Freeman MP, et al. Omega-3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. *Arch Gen Psychiatry* 1999;56:407–12.
 61. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind placebo-controlled trial. *Eur Neuropsychopharmacol* 2003;13:267–71.
 62. Iso H, Rexrode KM, Stampfer MJ, et al. Intake of fish and omega-3 fatty acids and risk of stroke in women. *JAMA* 2001;285:304–12.
 63. He K, Rimm EB, Merchant A, et al. Fish consumption and risk of stroke in men. *JAMA* 2002;288:3130–6.
 64. Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. *Arch Neurol* 2003;60:940–6.
 65. Hites RA, Foran JA, Carpenter DO, Hamilton MC, Knuth BA, Schwager SJ. Global assessment of organic contaminants in farmed salmon. *Science* 2004;303:226–9.
 66. Advice on fish consumption: benefits and risks [monograph on the internet]. London: United Kingdom Food Standards Agency; 2004 [cited 2004 Jul 20] Available from: <http://www.food.gov.uk/news/newsarchive/2004/jun/fishreport2004>.
 67. Guideline for assessing chemical contaminant data for use in fish advisories. Volume 2: risk assessment and fish consumption limits, 3rd ed. Washington DC: Environmental Protection Agency; [cited 2004 May 13]. Available from: <http://www.epa.gov/water/science/fishadvice/volume2/index.html>.
 68. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994;344:1383–9.
 69. Sacks FM, Pfeffer MA, Moye L, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. *N Engl J Med* 1996;335:1001–9.
 70. Guallar E, Sanz-Gallardo MI, van't Veer P, et al. Mercury, fish oils, and the risk of myocardial infarction. *N Engl J Med* 2003;347:1747–54.
 71. Yoshizawa K, Rimm EB, Morris JS, et al. Mercury and the risk of coronary heart disease in men. *N Engl J Med* 2002;347:1755–60.
 72. Substances affirmed as generally recognized as safe: menhaden oil, 21 C.F.R. Sect. 184.1472 (2001).
 73. Conner WE. Fish oil in hypertriglyceridemia: safety and recommendations [abstract]. *Lipids* 1999;34S:271.
 74. Montori VM, Farmer A, Wollan P, Dinneen SF. Fish oil supplementation in type 2 diabetes: a quantitative systematic review. *Diabetes Care* 2000;23:1407–15.
 75. Foran SE, Flood JG, Lewandrowski KB. Measurement of mercury levels in concentrated over-the-counter fish oil preparations. *Arch Pathol Lab Med* 2003;127:1603–5.